promising target for the treatment of immunological disease and cancer. Here, a succession of substituted hydrazino-thiazole derivatives were designed, synthesized, and biologically evaluated through structure-based optimization, of which compound 22 was the most potent inhibitor of hDHODH with an IC50 value of 1.8 nM. Furthermore, 22 exhibited much better antiproliferative activity than brequinar, both
已经证明抑制人二氢
乳清酸脱氢酶(h DHODH)会限制快速增殖的细胞的生长,因此h DHODH可作为治疗免疫性疾病和癌症的有希望的靶标。在这里,通过基于结构的优化设计,合成了一系列取代的
肼基
噻唑衍
生物,并对其进行了
生物学评估,其中化合物22是h DHODH的最有效
抑制剂,IC 50值为1.8 nM。此外,在HCT-116和BxPC-3癌
细胞系中,有22种抗增殖活性均优于
溴喹。流式细胞仪分析发现22诱导S期细胞周期停滞并促进凋亡诱导。所有结果证实了通过抑制限速酶h DHODH阻断
嘧啶从头合成途径是一种有吸引力的癌症治疗方法。